ARDX Stock Analysis: Buy, Sell, or Hold?

ARDX - Ardelyx, Inc.

PHARMACEUTICAL PREPARATIONS
$6.18
-0.19 (-2.98%) ▼
5d: +8.71%
30d: -2.68%
90d: +16.38%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Smart Money Accumulation

None View Scanner →

Strength: 5.7/10

Get Alerted When ARDX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
✅ BUY SIGNAL: ARDX trading at deep discount. Market pricing in -16.8% annual earnings decline, creating value opportunity for patient investors.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$15.01
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.32
33.7% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.8x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ARDX is currently trading at $6.18, which is considered slightly high relative to its 30-day fair value range of $5.60 to $6.21. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.0) compared to its historical average (20.8). Remarkably, the market is currently pricing in an annual earnings decline of 16.8% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ARDX is in a strong uptrend. Immediate support is located at $5.48, while resistance sits at $6.47.

Market Sentiment: ARDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $16.30 (+163.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $5.60 - $6.21
Company Quality Score 59/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 76.2%

All Signals

  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 163.8% below Wall St target ($16.30)

Trading Range Analysis

30-Day Trading Range $5.60 - $6.21
Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $5.48
Resistance Level $6.47
Current Trend Strong Uptrend
Technical data as of Jun 23, 2026

Fundamental Context

Forward P/E (Next Year Est.) 12.00
Wall Street Target $16.30 (+163.8%)
Revenue Growth (YoY) 27.5%
Profit Margin -13.6%
Valuation Discount vs History -16.8% cheaper
PE vs Historical 12.0 vs 20.8 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -16.8% (market-implied from PE analysis)
1-Year Target $5.56 (-10%)
2-Year Target $5.01 (-19%)
3-Year Target $4.51 (-27%)
3-Yr Target (if PE normalizes) (PE: 12→21) $7.81 (+26%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.0 to 20.8
Stabilization Target: $10.71 (+73.4%)
PE Expansion Potential: +73.4%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: June 24, 2026 3:08 AM ET
Data refreshes hourly during market hours. Next update: 4:08 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
1
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Raab SELL 41666 shares 2026-03-16
David M Mott BUY 333333 shares 2026-02-20
Susan Hohenleitner SELL 2033 shares 2026-02-20

Unlock Insider Activity

See real-time buying/selling by company executives for ARDX.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NTLA
Intellia Therapeutics Inc
STRONG BUY
29 analysts
$27 56 HOLD
ONC
BeiGene, Ltd.
STRONG BUY
24 analysts
$412 57 HOLD
INSM
Insmed Inc
STRONG BUY
21 analysts
$197 61 BUY
GPCR
Structure Therapeutics I…
STRONG BUY
14 analysts
$105 57 HOLD
RYTM
Rhythm Pharmaceuticals I…
STRONG BUY
12 analysts
$139 65 BUY

Advanced ARDX Option Strategies

Professional options setups generated by AI based on today's ARDX price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ARDX

ARDX Technical Chart ARDX Price Prediction ARDX Earnings Date ARDX Investment Advisor ARDX Fair Price Analyzer ARDX Options Advisor ARDX Options Chain ARDX Options Analysis ARDX Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals